(AGENPARL) – Mon 15 September 2025 Lund, Sweden, Monday 15 September, 2025. Hansa Biopharma AB, “Hansa” (Nasdaq
Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa
Biopharma will be presenting at the 16[th] Annual Pareto Securities Healthcare
Conference in Stockholm tomorrow, Tuesday 16 September, 10:40 CEST.
Aguiar-Lucander will also be participating in a panel discussion at 13:55 CEST
on current industry dynamics that will explore business deals, healthcare system
changes, and investor sentiment.
Event details: Hansa Biopharma AB Presentation
Date and time: Tuesday, September 16, 2025, 10:40 CEST
Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma
Event details: Panel Discussion on Current Industry Dynamics
Date and time: Tuesday, September 16, 2025, 13:55 CEST
Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma
For more information: Events & Conferences | Pareto Securities : Pareto
Securities (https://paretosec.com/updates/events-and-conferences)
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Kerstin Falck, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at http://www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/tw938nZbTkobRH5MJKLd99Fh5XhHoyRPJTYUj8ETg1JLXbxCRNym2B3SbuuQRPujVpCaphqzr972Y3fopJTvHV6MT5UmxBcA5RXSaEkUtMA5c.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/tw938nZbTkobRH5MJKLd99Fh5XhHoyRPJTYUj8ETg1JLXbxCRNym2B3SbuuQRPujVpCaphqzr972Y3fopJTvHV6MT5UmxBcA5RXSaEkUtMA5c.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content